Cases
Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)
Securities Class Action
Overview
Overview
- Date:
- 11/2/2015
- Company Name:
- Northwest Biotherapeutics, Inc.
- Stock Symbol:
- NWBO
- Status:
- Closed/Complete
NEW YORK, November 2, 2015 – Bragar Eagel & Squire, P.C. is investigating potential claims on behalf of Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) investors concerning whether the company’s officers and board of directors violated their fiduciary duties.
On June 19, 2014 shares of the Company fell $2.06, or 22.97%, during intraday trading after a report featured on TheStreet.com stated, “The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.” MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics. According to the report, investigators at MD Anderson, one of several sites conducting the study, have not yet been able to analyze data collected because patients are still being enrolled and treated in the study.
If you are a Northwest Biotherapeutics, Inc. stockholder and have information that could assist in this investigation, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.
On June 19, 2014 shares of the Company fell $2.06, or 22.97%, during intraday trading after a report featured on TheStreet.com stated, “The prestigious MD Anderson Cancer Center issued a stern rebuke to Northwest Biotherapeutics (NWBO) for making promotional, unjustified claims about results from an ongoing clinical trial of an experimental cancer vaccine known as DCVax-Direct.” MD Anderson Cancer Center is running the DCVax-Direct clinical trial with funding from Northwest Biotherapeutics. According to the report, investigators at MD Anderson, one of several sites conducting the study, have not yet been able to analyze data collected because patients are still being enrolled and treated in the study.
If you are a Northwest Biotherapeutics, Inc. stockholder and have information that could assist in this investigation, please contact Melissa A. Fortunato, Esq. by email at investigations@bespc.com, or telephone at (212) 355-4648, or by filling out the contact form below. There is no cost or obligation to you.